Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Exelixis Inc (EXEL)
Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,743,035
  • Shares Outstanding, K 303,194
  • Annual Sales, $ 1,830 M
  • Annual Income, $ 207,770 K
  • 60-Month Beta 0.53
  • Price/Sales 3.63
  • Price/Cash Flow 28.44
  • Price/Book 2.93
Trade EXEL with:

Options Overview Details

View History
  • Implied Volatility 45.52% ( +7.45%)
  • Historical Volatility 29.37%
  • IV Percentile 99%
  • IV Rank 89.10%
  • IV High 48.60% on 12/01/23
  • IV Low 20.31% on 06/21/23
  • Put/Call Vol Ratio 0.21
  • Today's Volume 8,976
  • Volume Avg (30-Day) 2,512
  • Put/Call OI Ratio 1.34
  • Today's Open Interest 46,034
  • Open Int (30-Day) 46,770

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.23
  • Number of Estimates 8
  • High Estimate 0.36
  • Low Estimate 0.16
  • Prior Year 0.12
  • Growth Rate Est. (year over year) +91.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.01 +11.12%
on 02/12/24
22.63 -1.72%
on 03/01/24
+0.49 (+2.25%)
since 02/01/24
3-Month
19.20 +15.83%
on 01/08/24
24.34 -8.63%
on 01/02/24
+0.30 (+1.37%)
since 12/01/23
52-Week
16.15 +37.75%
on 03/08/23
24.34 -8.63%
on 01/02/24
+4.77 (+27.30%)
since 03/01/23

Most Recent Stories

More News
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.

COMP : 3.85 (-2.53%)
$NASX : 16,274.94 (+1.14%)
MA : 476.63 (+0.39%)
PUBM : 21.07 (+0.62%)
EXEL : 22.24 (+1.55%)
AMZN : 178.22 (+0.83%)
Jumpstart Your Portfolio With These 3 Biotech Stocks

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech...

BMY : 50.89 (+0.28%)
EXEL : 22.24 (+1.55%)
RCUS : 19.10 (-0.16%)
VNDA : 4.61 (+3.13%)
VRTX : 432.76 (+2.86%)
Moderna (MRNA) Earnings Analysis: Buy or Watch for Gains?

Moderna’s (MRNA) mRNA platform is positioned to deliver significant long-term impact with its mRNA medicines, but declining sales amid plummeting demand for its COVID-19 vaccine, steep losses, and cash...

EXEL : 22.24 (+1.55%)
GILD : 72.31 (+0.29%)
INCY : 59.05 (+1.18%)
MRNA : 95.06 (+3.06%)
2 Stocks Under $30 to Buy and Hold

You don't need to be a millionaire to get started. Investing on a budget can work, too.

ADYEY : 15.8700 (+0.44%)
EXEL : 22.24 (+1.55%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

ONCY : 1.1200 (-1.75%)
ONC.TO : 1.51 (+0.67%)
EXEL : 22.24 (+1.55%)
PFE : 26.59 (+0.11%)
BTAI : 3.21 (+0.94%)
BMY : 50.89 (+0.28%)
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

ONCY : 1.1200 (-1.75%)
ONC.TO : 1.51 (+0.67%)
EXEL : 22.24 (+1.55%)
PFE : 26.59 (+0.11%)
BTAI : 3.21 (+0.94%)
BMY : 50.89 (+0.28%)
Elite 4 Biotech Stocks to Buy Now for Explosive Returns

With a wide range of applications across sectors, including health, agriculture, and industrial processing, rapid technological adoption, and government support, the biotech industry’s prospects appear...

BMY : 50.89 (+0.28%)
CORT : 24.06 (+2.38%)
EXEL : 22.24 (+1.55%)
INCY : 59.05 (+1.18%)
JAZZ : 118.85 (-0.04%)
MOR : 17.70 (+0.57%)
RCUS : 19.10 (-0.16%)
Biogen (BIIB): Earnings Alert - Key Insights

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate...

BIIB : 220.95 (+1.82%)
CORT : 24.06 (+2.38%)
EXEL : 22.24 (+1.55%)
INCY : 59.05 (+1.18%)
4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.

COMP : 3.85 (-2.53%)
$NASX : 16,274.94 (+1.14%)
NIO : 5.78 (+0.52%)
LOVE : 23.16 (+0.52%)
EXEL : 22.24 (+1.55%)
GOOGL : 137.14 (-0.95%)
GOOG : 138.08 (-1.22%)
Exelixis (EXEL) Q4 2023 Earnings Call Transcript

EXEL earnings call for the period ending December 31, 2023.

EXEL : 22.24 (+1.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 23.20
2nd Resistance Point 22.91
1st Resistance Point 22.58
Last Price 22.24
1st Support Level 21.96
2nd Support Level 21.67
3rd Support Level 21.34

See More

52-Week High 24.34
Last Price 22.24
Fibonacci 61.8% 21.21
Fibonacci 50% 20.24
Fibonacci 38.2% 19.28
52-Week Low 16.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar